Hot Picks: Biotech sector draws investor attention ahead of key data [BNN Bloomberg (Canada)]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: BNN Bloomberg
Analysts are watching how dosing convenience, known biological targets and late-stage pipelines could shape sentiment in the sector. BNN Bloomberg spoke with David Nierengarten, senior analyst at Wedbush, about biotech stocks he sees as well positioned, including companies developing therapies for autoimmune conditions, blood disorders and recurrent pericarditis. Key Takeaways Biotech investors are watching multiple near-term clinical data readouts that could act as catalysts across the sector. Autoimmune drug development is increasingly focused on well-understood targets paired with improved dosing convenience. Rare disease therapies can face short-term volatility around regulatory reviews without materially changing long-term value. Commercial-stage drugs with growing cash flow can provide stability within small- and mid-cap biotech names. Follow-on assets and wholly owned next-generation therapies may significantly expand margins and acquisition appeal. Read the ful
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
- Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 1/23/26 - Form 4
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- SYRE's page on the SEC website